3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
80
Recurrence
17
Neoplasms, Plasma Cell
9
Immunoglobulin Light-chain Amyloidosis
9
Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Amyloidosis
3
Waldenstrom Macroglobulinemia
2
Polycythemia Vera
2
Paraproteinemias
2
Myeloproliferative Disorders
2
Lymphoma, B-Cell
2
Hematologic Diseases
2
Chromosome 17 deletion
2
Burkitt Lymphoma
2
Blood Protein Disorders
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Smoldering Multiple Myeloma
1
Renal Insufficiency
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Plasmacytoma
1
Pancreatic Neoplasms
1
Neoplasms by Histologic Type
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Plasma Cell
1
Interventions
fludarabine phosphate
4
Dexamethasone
4
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
pomalidomide
2
ibrutinib
2
Whole-Body Irradiation
2
Tacrolimus
2
Mycophenolic Acid
2
venetoclax
1
ixazomib
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
auricularum
1
Sirolimus
1
RG7388
1
Nivolumab
1
Maintenance
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cyclosporine
1
Cyclophosphamide
1
Carmustine
1
Calcium Dobesilate
1
Bortezomib
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Chromosome 17 deletion
×
pomalidomide
×
Clear all
NCT01745640
2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2
Completed
63 enrolled
NCT04124497
2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2
Active not recruiting
45 enrolled